User profiles for T M Burns

Ted M Burns, MD

University of Virginia
Verified email at virginia.edu
Cited by 8008

Vasculitic neuropathies

KG Gwathmey, TM Burns, MP Collins… - The Lancet …, 2014 - thelancet.com
The vasculitic neuropathies are a diverse group of disorders characterised by the acute-to-subacute
onset of painful sensory and motor deficits that result from inflammatory destruction …

[HTML][HTML] Guillain-barré syndrome

TM Burns - Seminars in neurology, 2008 - thieme-connect.com
… [12] The carbohydrate moieties of gangliosides elicit a T-cell-independent humoral response,
and antiganglioside antibodies exist as low-affinity IgM isotypes in normal subjects. The …

Quality of life and measures of quality of life in patients with neuromuscular disorders

TM Burns, CD Graham, MR Rose, Z Simmons - Muscle & nerve, 2012 - Wiley Online Library
In this review we present an overview of quality of life (QOL) and QOL measures in neuromuscular
disorders. We discuss the characteristics of QOL measures used in neuromuscular …

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double …

…, RJ Barohn, I Illa, S Jacob, J Vissing, TM Burns… - The Lancet …, 2017 - thelancet.com
Background Complement is likely to have a role in refractory generalised myasthenia gravis,
but no approved therapies specifically target this system. Results from a phase 2 study …

The genome organization of banana bunchy top virus: analysis of six ssDNA components

TM Burns, RM Harding, JL Dale - Journal of General …, 1995 - microbiologyresearch.org
We have cloned, sequenced and analysed an additional five circular ssDNA components of
banana bunchy top virus (BBTV) which we have called components 2, 3, 4, 5 and 6. These …

The MG Composite: a valid and reliable outcome measure for myasthenia gravis

TM Burns, M Conaway, DB Sanders - Neurology, 2010 - AAN Enterprises
Objective: To study the concurrent and construct validity and test-retest reliability in the
practice setting of an outcome measure for myasthenia gravis (MG). Methods: Eleven centers …

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis

…, RJ Barohn, I Illa, S Jacob, J Vissing, TM Burns… - Muscle & …, 2019 - Wiley Online Library
TM Burns has served as a paid consultant for Argenx and CSL Behring. JT Kissel has
received support from Alexion Pharmaceuticals, aTyr Pharma, Cytokinetics Novartis, Sanofi …

Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review

…, MA Fellman, SM Greene, M Pasnoor, TM Burns - Neurology, 2017 - AAN Enterprises
… Means were analyzed with 2-tailed t test and medians analyzed with the Wilcoxon rank sum
… Pasnoor, and T. Burns report no disclosures relevant to the manuscript. Go to Neurology.org …

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

JF Howard Jr, V Bril, TM Burns, R Mantegazza… - Neurology, 2019 - AAN Enterprises
Objective To investigate safety and explore efficacy of efgartigimod (ARGX-113), an anti-neonatal
Fc receptor immunoglobulin G1 Fc fragment, in patients with generalized myasthenia …

Less is more, or almost as much: a 15‐item quality‐of‐life instrument for myasthenia gravis

TM Burns, MR Conaway, GR Cutter… - Muscle & …, 2008 - Wiley Online Library
We describe the process whereby a recently developed myasthenia gravis (MG)‐specific
quality‐of‐life (QOL) instrument was reduced from 60 items to 15 items while maintaining …